Currency In USD
| Previous Close | 2.27 |
| Open | 2.36 |
| Day High | 2.37 |
| Day Low | 2.22 |
| 52-Week High | 3.11 |
| 52-Week Low | 0.29 |
| Volume | 2.25M |
| Average Volume | 2.53M |
| Market Cap | 296.74M |
| PE | -10.71 |
| EPS | -0.21 |
| Moving Average 50 Days | 2.6 |
| Moving Average 200 Days | 1.88 |
| Change | -0.02 |
Ovid Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Feb 25, 2026 12:00 PM GMT
NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines to treat brain disorders and symptoms caused by excess neural excitability, today announced that the
Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)
GlobeNewswire Inc.
Dec 18, 2025 1:00 PM GMT
OV350 showed a good safety profile, supporting the advancement of the Company’s KCC2 portfolio, including the first oral direct activator, OV4071There were no treatment-related laboratory findings, no safety findings, and no treatment-related serious
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer
GlobeNewswire Inc.
Dec 02, 2025 12:00 PM GMT
NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today announced the appointment of Petra Kaufmann, M